Search for: "Bayer Aktiengesellschaft"
Results 1 - 20
of 28
Sorted by Relevance
|
Sort by Date
11 Nov 2007, 1:28 pm
In Re Bayer Aktiengesellschaft, Federal U.S. [read post]
25 May 2007, 9:50 am
Bayer Aktiengesellschaft continues to experience headache in trying to trademark "ASPIRINA": A divided three-judge panel of the U.S. [read post]
24 May 2007, 3:07 pm
In re Bayer Aktiengesellschaft, No. 2006-1279 (Fed. [read post]
21 Oct 2007, 7:40 pm
Bayer Aktiengesellschaft et al. 1:07-cv-05875; filed October 17, 2007 in the Northern District... [read post]
25 May 2007, 5:00 am
In re Bayer Aktiengesellschaft, Appeal No. 2006-1279 (May 24, 2007) [precedential].The Examining Attorney relied on numerous NEXIS excerpts and two dictionary definitions in which ASPIRINA was defined as aspirin. [read post]
27 Jan 2013, 11:59 pm
Bayer Pharma Aktiengesellschaft v Genentech, Inc. [2012] FCA 1467 (20 December 2012)The Australian Federal Court has ruled that biotechnology company Genentech Inc can serve a claim of infringement of an Australian patent on Regeneron Pharmaceuticals Inc at the address of its New York headquarters. [read post]
20 Mar 2017, 6:39 pm
In Bayer Pharma Aktiengesellschaft v Generic Health Pty Ltd [2017] FCA 250, Bayer was awarded damages of over $25m plus interest, assessed on Bayer’s pre-tax losses. [read post]
21 Apr 2013, 1:42 am
Bayer Pharma Aktiengesellschaft v Generic Health Pty Ltd (No 2) [2013] FCA 279 (4 April 2013)Dr James Rowe has had over 30 years’ experience in the pharmaceutical industry. [read post]
28 Apr 2013, 8:08 am
Bayer Pharma Aktiengesellschaft v Generic Health Pty Ltd (No 2) [2013] FCA 279 (4 April 2013)The Federal Court has again confirmed that, contrary to the impression you might obtain from reading IP Australia’s Patent Examiners Manual, ‘obvious’ or ‘worthwhile’ to try does not form part of the test for inventive step under Australian patent law. [read post]
26 Jul 2014, 9:14 pm
We continue to await decisions from the Australian court in both the Myriad and the Research Affiliates cases.While the delays in deciding these cases are not inconsiderable, they do not appear to be particularly unusual by current standards of the Full Court – another recently-decided patents appeal, Generic Health Pty Ltd v Bayer Pharma Aktiengesellschaft [2014] FCAFC 73, was heard on 26-27 August 2013, with judgment handed down on 19 May 2014. [read post]
20 Apr 2022, 10:40 am
” In re Bayer Aktiengesellschaft, 488 F.3d 960, 963 (Fed. [read post]
24 May 2007, 1:36 pm
While the evidence of record was conflicting as to whether ASPIRINA was descriptive, given the deferential standard of review, the panel majority affirmed the decision to deny registration to Bayer.Judge Newman dissented, and would have given more weight to the fact that ASPIRINA is a registered mark in 34 foreign countries, and the fact that the applicant was policing use of the term online.More details of In re Bayer Aktiengesellschaft after the jump. [read post]
7 Jun 2010, 1:59 am
Bayer Aktiengesellschaft v. [read post]
10 Jan 2008, 7:39 am
For example, In Re Bayer Aktiengesellschaft, Serial No. 78/212,751 (US Ct. [read post]
28 Mar 2017, 9:03 am
” In re Bayer Aktiengesellschaft, 488 F.3d 960,970 (Fed. [read post]
13 Aug 2009, 6:57 am
Hence, the Board argues, the skilled expert would, having read the patent, still need to do a complete research programme in order to find that out.It appears to be a case of bad claim drafting: The wording merely appears to reflect the fantasy of an employee at Bayer Schering Pharma Aktiengesellschaft, desperately eager to cover each and every solution to the objective of stimulating some enzyme but who has no idea as to which compounds in particular might be suitable to do so the… [read post]
22 Jun 2018, 3:31 pm
Princeton Vanguard, 786 F.3d at 964(citing In re Hotels.com, LP, 573 F.3d 1300, 1301 (Fed.Cir. 2009)); In re Bayer Aktiengesellschaft, 488 F.3d 960,964 (Fed. [read post]
24 Jun 2017, 8:08 pm
These issues were recently considered by Justice Jagot in the Federal Court decision Bayer Pharma Aktiengesellschaft v Generic Health Pty Ltd [2017] FCA 250, who confirmed that ‘the words “reasonable skill and knowledge” require the specification as framed to be in the form in which a person, with reasonable skill in drafting patent specifications and a knowledge of the relevant law and practice, would produce given the patentee's knowledge of the… [read post]
4 Apr 2012, 8:53 am
” In re Bayer Aktiengesellschaft, 488 F.3d 960, 963 (Fed. [read post]
16 Jun 2010, 3:02 pm
Novartis Animal Health US, Inc (Docket Report) US: Finding ORGANIC ASPIRIN deceptively misdescriptive of and deceptive for dietary supplements, TTAB sustains Bayer opposition: Bayer Aktiengesellschaft v. [read post]
